Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by $1.38, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $1.53, $1.38 better than the analyst estimate of $0.15. Revenue for the quarter came in at $77.1 million versus the consensus estimate of $74.41 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Barclays Starts Hawkins (HWKN) at Equalweight
• Vital Farms (VITL) PT Raised to $13 at Jefferies